Want to see ENOV full AI Analyst Report?
ENOV Stock Chart & Stats
$25.25
$1.22(4.51%)
At close: 4:00 PM EDT
$25.25
$1.22(4.51%)
Day’s Range― - ―
52-Week Range$16.70 - $34.28
Previous Close$28.25
Volume827.69K
Average Volume (3M)1.79M
Market Cap
$1.19B
Enterprise Value$2.65B
Total Cash (Recent Filing)$12.56M
Total Debt (Recent Filing)$1.37B
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Nov 05, 2026EPS Estimate
0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.40
Shares Outstanding57,669,495
10 Day Avg. Volume1,358,209
30 Day Avg. Volume1,787,980
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.02
Price to Sales (P/S)0.67
P/FCF Ratio75.96
Enterprise Value/Market Cap2.22
Enterprise Value/Revenue1.16
Enterprise Value/Gross Profit2.01
Enterprise Value/Ebitda-3.70
Forecast
1Y Price Target
$36.20Price Target Upside43.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)3.63
Revenue Forecast (FY)$2.34B
Bulls Say, Bears Say
Bulls Say
Organic Growth And Share GainsPositive organic growth across both segments, particularly in Reconstruction, indicates continued demand and commercial execution. Growth in hips, knees, shoulders, and extremities, together with reported share-gain opportunities, can support durable revenue expansion over the next several quarters.
Product Innovation And AdoptionNebula conversions and the commercial launch of ARVIS strengthen Enovis’s technology and product portfolio. Adoption by competitive users and positive early feedback can deepen surgeon engagement, support account wins, and create a foundation for sustained share gains.
Improving Cash Flow And MarginsImproving margins and sharply higher free cash flow show progress toward better earnings quality and internal funding capacity. Reaffirmed expectations for over 25% free-cash-flow conversion would strengthen debt reduction and provide more flexibility for innovation and growth investment.
Bears Say
Large Ongoing Net LossesVery large reported losses remain the clearest fundamental weakness and indicate that revenue growth has not yet translated into consistent GAAP earnings power. Until profitability improves materially, Enovis may have less resilience to operational setbacks and less capacity to fund expansion from earnings.
Elevated LeverageLeverage near the level of equity limits financial flexibility relative to a less indebted balance sheet. Although management is targeting leverage below three times, debt reduction depends on sustained cash generation, making capital allocation and execution more consequential over the coming quarters.
Inflation And Pricing PressurePersistent inflation can pressure margins when contractual and competitive conditions prevent full price recovery. The issue is especially relevant in Prevention & Recovery, where management has already identified difficulty passing through costs, potentially limiting the durability of margin expansion.
Enovis News
ENOV FAQ
What was Enovis’s price range in the past 12 months?
Enovis lowest stock price was $16.70 and its highest was $34.28 in the past 12 months.
What is Enovis’s market cap?
Enovis’s market cap is $1.19B.
When is Enovis’s upcoming earnings report date?
Enovis’s upcoming earnings report date is Nov 05, 2026 which is in 14 days.
How were Enovis’s earnings last quarter?
Enovis released its earnings results on Aug 06, 2026. The company reported $0.9 earnings per share for the quarter, beating the consensus estimate of $0.847 by $0.053.
Is Enovis overvalued?
According to Wall Street analysts Enovis’s price is currently Undervalued.
Does Enovis pay dividends?
Enovis does not currently pay dividends.
What is Enovis’s EPS estimate?
Enovis’s EPS estimate is 0.77.
How many shares outstanding does Enovis have?
Enovis has 57,669,495 shares outstanding.
What happened to Enovis’s price movement after its last earnings report?
Enovis reported an EPS of $0.9 in its last earnings report, beating expectations of $0.847. Following the earnings report the stock price went down -12.823%.
Which hedge fund is a major shareholder of Enovis?
Currently, no hedge funds are holding shares in ENOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enovis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.20 (43.37% Upside)
$36.20 (43.37% Upside)
Blogger Sentiment
Bullish
ENOV Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 270.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $449.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 11.2%
Last 30 Days ▲ 11.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.47%
12-Months-Change
Fundamentals
Return on Equity
-68.17%
Trailing 12-Months
Asset Growth
-25.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Enovis
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
ENOV Company Deck
ENOV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive. Enovis delivered 5% organic growth, strong U.S. Recon and new-product momentum, improved margins, higher adjusted EPS, a significant improvement in free cash flow, and progress on deleveraging while reaffirming 2026 guidance. The principal challenges were inflation, tariffs, Middle East-related disruption, softer Western European markets, and a seasonally more difficult third quarter, but management expressed confidence in commercial execution and second-half acceleration.View all ENOV earnings summariesENOV Stock 12 Month Forecast
Average Price Target
$36.20
▲(43.37% Upside)
Technical Analysis
Conmed
―
Integra Lifesciences
―
Smith & Nephew Snats
―
Stryker
―
Zimmer Biomet Holdings
―
Ownership Overview
2.27% Insiders
40.04% Mutual Funds
1.36% Other Institutional Investors
19.80% Public Companies and
Individual Investors